deCODE Genetics Announces Full-year 2007 Financi...(aggregation as well as platelet ac...)

platelet activation mediated specifically through vasodilator

stimulated phosphoprotein (VASP), a biomarker useful for measuring

platelet activity. These effects were concentration-dependent and were

seen irrespective of whether patients were receiving concomitant

therapy with aspirin. The company is building upon these successful

results with a second clinical pharmacology study of the effects of

DG041 when taken with aspirin and Plavix(TM). deCODE is also working on

a once-daily formulation for DG041.

-- Heart attack: DG051 & DG031. In 2007 deCODE completed Phase I and phase

IIa clinical testing of DG051, the company's developmental compound for

the prevention of heart attack. DG051, discovered by deCODE chemists,

is designed to counter risk of heart attack by reining in the activity

of the leukotriene pathway, reducing the production of leukotriene B4

(LTB4). LTB4 is a pro-inflammatory molecule that deCODE's gene

discovery and functional biology work identified as a one of the

factors modulating risk of heart attack. deCODE's clinical studies to

date have showed DG051 to reduce LTB4 production in a dose-dependent

manner, even in cardiovascular patients taking concomitant medications.

deCODE has also completed the reformulation of DG031, its other

compound targeting the leukotriene pathway for the prevention of heart

attack, and is actively seeking a partner with whom to take the next

step in development of its leukotriene program.

Target Discovery

-- deCODE has continued to lead the world in the discovery of common

genetic variants linked to significantly increased risk of common

diseases. Since the beginning of 2007, deCODE has discovered novel

variants conferring risk of type 2 diabetes, prostate cancer,
'/>"/>